Finch Therapeutics Group, Inc.

FNCH

Finch Therapeutics Group, Inc.

FNCH

Insider Sentiment (TTM):

Last Purchase:2023-06-09Last Sale:2024-03-28Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2024-06-30Institutional Shares Owned:21,206Shares Outstanding:1,605,763Institutional Ownership Pct.:1.32%

Earnings Market Reaction:

Filing Date:2024-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30
Assets
Cash And Cash Equivalents At Carrying Value	16	21	25	29	34	42	71	85	105	107	133	149
Accounts Receivable Net Current	-	-	0	0	0	0	0	0	0	0	0	2
Assets Current
Assets Current	17	21	26	30	36	43	75	91	111	123	143	156
Prepaid Expense And Other Assets Current	1	0	1	1	2	2	3	5	6	16	9	5
Due From Related Parties Current	-	-	-	-	-	-	-	-	-	-	0	0
Property Plant And Equipment Net	1	1	1	1	1	1	16	17	18	19	20	20
Operating Lease Right Of Use Asset	25	26	27	27	27	32	33	40	41	5	5	5
Restricted Cash Noncurrent	2	2	2	2	2	2	3	3	3	2	2	2
Other Assets Noncurrent	-	-	0	0	0	0	4	4	5	5	5	4
Unamortized Debt Issuance Expense	-	-	-	-	-	-	-	-	-	-	0	0
Assets	46	50	55	59	67	79	163	188	228	205	225	233
Liabilities And Stockhold…
Accounts Payable Current	0	0	0	0	0	3	1	1	1	5	4	1
Liabilities Current
Goodwill	-	-	-	-	-	-	0	0	18	18	18	18
Liabilities Current	4	3	4	5	10	13	15	14	15	17	15	9
Operating Lease Liability Current	2	2	2	2	2	3	3	3	5	1	1	1
Deferred Income Tax Liabilities Net	-	-	0	0	0	0	3	3	3	3	3	3
Long Term Debt Noncurrent	-	-	0	0	0	0	15	15	15	-	0	0
Due To Related Parties Current	-	-	-	-	-	-	-	-	-	-	0	0
Operating Lease Liability Noncurrent	27	28	28	29	29	33	34	35	36	5	5	5
Contract With Customer Liability Current	-	-	-	-	-	-	-	-	-	-	0	0
Other Liabilities Noncurrent	-	-	0	0	0	0	0	0	0	0	0	0
Liabilities	31	31	32	34	39	46	67	67	69	25	23	13
Contract With Customer Liability Noncurrent	-	-	-	-	-	-	-	-	-	-	0	0
Preferred Stock Value	0	0	0	0	0	0	0	-	-	-	0	-
Deferred Rent Credit Noncurrent	-	-	-	-	-	-	-	-	-	-	0	1
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders Equity
Stockholders Equity	14	19	23	26	28	35	96	121	159	180	202	220
Additional Paid In Capital Common Stock	373	373	373	373	373	372	371	369	367	365	363	362
Retained Earnings Accumulated Deficit	-359	-354	-350	-347	-345	-340	-276	-249	-208	-186	-161	-142
Liabilities And Stockholders Equity	46	50	55	59	67	79	163	188	228	205	225	233
Temporary Equity Shares Authorized	10	10	10	10	10	10	10	-	-	-	10	-
Temporary Equity Shares Issued	0	0	0	0	0	0	0	-	-	-	0	-
Temporary Equity Shares Outstanding	0	0	0	0	0	0	0	-	-	-	0	0
Temporary Equity Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	-	-	-	0.001	-
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	2	2	2	2	2	2	2	2	2	2	2	2
Shares Outstanding	2	2	2	2	2	2	2	2	2	2	2	2
Series A Redeemable Convertible Preferred Stock	-	-	-	-	-	-	0	-	-	-	0	0
Series B Redeemable Convertible Preferred Stock	-	-	-	-	-	-	0	-	-	-	0	0
Series C Redeemable Convertible Preferred Stock	-	-	-	-	-	-	0	-	-	-	0	0
Series D Redeemable Convertible Preferred Stock	-	-	-	-	-	-	0	-	-	-	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2024	-51.89%	-31.84%	-7.46%	24.28%	15.86%	20.42%	-	-	-	-	-	-
2023	-24.05%	-28.02%	-30.38%	-4.39%	-21.52%	-43.33%	18.47%	-4.75%	-23.48%	-17.04%	-28.15%	-46.67%
2022	28.04%	23.83%	5.61%	-9.92%	-36.26%	-48.85%	-8.57%	-54.29%	-50.48%	-2.00%	-10.50%	-32.25%
2021	-	-	-	-	-	-	6.09%	-30.96%	-43.77%	-45.13%	-54.67%	-47.91%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30
Liquidity Ratios
Current Ratio	3.87	6.05	6.33	6.13	3.81	3.29	5.08	6.56	7.28	7.31	9.64	17.64
Quick Ratio	3.59	5.93	6.15	5.90	3.56	3.16	4.85	6.18	6.91	6.38	9.06	17.13
Working Capital	12.82M	17.68M	21.76M	25.04M	26.92M	30.19M	59.86M	76.81M	95.36M	105.86M	127.76M	147.32M
Leverage & Debt
Debt to Equity	2.21	1.63	1.42	1.30	1.40	1.33	0.70	0.56	0.44	0.14	0.11	0.06
Debt Ratio	0.69	0.62	0.59	0.57	0.58	0.58	0.41	0.36	0.30	0.12	0.10	0.06
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.05	0.07	0.08	-
Days Sales Outstanding TTM	-	-	-	-	-	82.93	135.23	-	34.32	28.84	9.73	-
Receivables Turnover TTM	-	-	-	-	-	4.40	2.70	-	10.64	12.66	37.51	-
Per Share Metrics
Diluted EPS TTM	-8.82	-10.14	-46.59	-61.51	-85.17	-95.10	-72.12	-67.06	-48.09	-43.44	-44.55	-
Free Cash Flow Per Share TTM	-11.25	-14.01	-19.65	-26.25	-35.08	-39.85	-48.46	-49.34	-47.79	-54.10	-63.67	-
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Margin Metrics
Operating Profit Margin TTM	-	-	-78,374.77%	-93,214.78%	-56,935.97%	-25,536.81%	-13,425.44%	-6,443.82%	-592.38%	-460.39%	-323.68%	-
Net Profit Margin TTM	-	-	-69,863.55%	-85,844.35%	-54,022.13%	-24,825.08%	-13,315.45%	-6,431.16%	-592.95%	-448.35%	-313.84%	-
Growth Metrics
Net Revenue Growth (1Y)	-100.00%	-100.00%	-87.57%	-93.07%	-98.03%	-96.00%	-95.35%	-	-	-	-	-
Net Income Growth (1Y)	-89.63%	-89.32%	-34.80%	-7.47%	79.18%	121.72%	97.12%	-	-	-	-	-
EPS Growth (1Y)	-89.64%	-89.34%	-35.40%	-8.28%	77.08%	118.94%	61.88%	-	-	-	-	-
Calculated Values
Free Cash Flow TTM	-18.07M	-22.50M	-31.53M	-42.14M	-56.30M	-63.87M	-77.03M	-78.50M	-75.79M	-85.62M	-83.12M	-
Net Debt	-16.04M	-20.76M	-25.12M	-28.78M	-34.05M	-41.68M	-56.39M	-70.66M	-90.05M	-106.93M	-133.48M	-149.20M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2024-03-28Sale

Owner: Smisek, Jeffery A

Title: -

Shares: 6,642

Price/Share: $2.57

Value: $17,069.94

Shares Owned: -

Relationship: Director

Ownership: Direct

2023-11-22Sale

Owner: Smisek, Jeffery A

Title: -

Shares: 1,470

Price/Share: $3.64

Value: $5,350.80

Shares Owned: 6,642

Relationship: Director

Ownership: Direct

2023-06-09Purchase

Owner: Graf, Susan E

Title: -

Shares: 5,010

Price/Share: $0.27

Value: $1,352.70

Shares Owned: 5,010

Relationship: Director

Ownership: Direct

2023-02-21Sale

Owner: Blaustein, Marc

Title: Chief Operating Officer

Shares: 4,619

Price/Share: $0.38

Value: $1,755.22

Shares Owned: 27,995

Relationship: Officer

Ownership: Direct

2022-10-21Sale

Owner: Blaustein, Marc

Title: Chief Operating Officer

Shares: 3,636

Price/Share: $1.39

Value: $5,054.04

Shares Owned: 32,614

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2024-03-28	Smisek, Jeffery A	Director	-	Direct	Sale	6,642	2.57	$17,069.94	0	4
2023-11-22	Smisek, Jeffery A	Director	-	Direct	Sale	1,470	3.64	$5,350.80	6,642	4
2023-06-09	Graf, Susan E	Director	-	Direct	Purchase	5,010	0.27	$1,352.70	5,010	4
2023-02-21	Blaustein, Marc	Officer	Chief Operating Officer	Direct	Sale	4,619	0.38	$1,755.22	27,995	4
2022-10-21	Blaustein, Marc	Officer	Chief Operating Officer	Direct	Sale	3,636	1.39	$5,054.04	32,614	4
2022-10-21	Vittiglio, Joseph	Officer	Chief Business & Legal Officer	Direct	Sale	3,636	1.39	$5,054.04	31,364	4
2021-12-20	Haft, Nicholas	Director	-	Indirect	Purchase	63,850	10.18	$649,993.00	4,056,907	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2024-06-30

1.32%

Inst. Shares: 21,206

Shares Outstanding: 1,605,763

2024-03-31

8.04%

Inst. Shares: 129,112

Shares Outstanding: 1,605,763

2023-12-31

6.79%

Inst. Shares: 108,988

Shares Outstanding: 1,604,549

2023-09-30

10.99%

Inst. Shares: 176,388

Shares Outstanding: 1,604,967

2023-06-30

6.42%

Inst. Shares: 102,971

Shares Outstanding: 1,604,795

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2024-06-30	21,206	1,605,763	1.32%
2024-03-31	129,112	1,605,763	8.04%
2023-12-31	108,988	1,604,549	6.79%
2023-09-30	176,388	1,604,967	10.99%
2023-06-30	102,971	1,604,795	6.42%
2023-03-31	6,644,705	1,602,852	-
2022-12-31	6,827,606	1,589,584	-
2022-09-30	10,040,301	1,590,938	-
2022-06-30	9,862,381	1,585,978	-
2022-03-31	10,538,287	47,528,948	22.17%
2021-12-31	10,780,703	39,202,086	27.50%
2021-09-30	8,213,299	47,445,195	17.31%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Finch Therapeutics Group, Inc. (FNCH) — SEC Financial Statements & Analysis

Finch Therapeutics Group, Inc. (FNCH) is a biological products, (no diagnostic substances) company, incorporated in DE. Finch Therapeutics Group, Inc. trades on OTC as: FNCH. Based on its latest SEC filing (Form 10-Q, period ending 2024-06-30), Finch Therapeutics Group, Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 2.21x. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 2.21x

Data as of 2024-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Finch Therapeutics Group, Inc. in?

Finch Therapeutics Group, Inc. (FNCH) operates in the Biological Products, (No Diagnostic Substances) industry.

What exchange does FNCH trade on?

Finch Therapeutics Group, Inc. (FNCH) trades on the OTC.

Where is Finch Therapeutics Group, Inc. incorporated?

Finch Therapeutics Group, Inc. is incorporated in DE.